| Nov 13 |
Amgen dismisses bone density concerns related to its new weight-loss drug
|
| Nov 13 |
AMGEN PROVIDES STATEMENT ON MARITIDE PHASE 1 DATA
|
| Nov 12 |
Amgen Drops 7% After A 'Big Unknown Risk' Rattles Its Monthly Obesity Shot
|
| Nov 12 |
Amgen slips as Cantor cites safety concerns linked to obesity candidate
|
| Nov 8 |
AMGEN TO PRESENT AT THE 2024 UBS GLOBAL HEALTHCARE CONFERENCE
|
| Nov 8 |
AstraZeneca and Amgen’s Tezspire succeeds in Phase III nasal polyps trial
|
| Nov 8 |
AstraZeneca/Amgen's Asthma Drug Aces Late-Stage Study In Patients With Chronic Rhinosinusitis
|
| Nov 8 |
Amgen, AstraZeneca post Phase 3 win for nasal polyps therapy
|
| Nov 8 |
TEZSPIRE MET BOTH CO-PRIMARY ENDPOINTS IN PHASE 3 TRIAL FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
|
| Nov 7 |
Amgen Insiders Sold US$4.0m Of Shares Suggesting Hesitancy
|
